Author

S. Bidlingmaier

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 3 Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:drug response / drug discovery· 4 Organism:mouse· 3 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

B. Liu· 5 shared Y. Su· 5 shared N.-K. Lee· 3 shared Y. Seo· 3 shared J. He· 2 shared R. R. Flavell· 2 shared A. Bidkar· 1 shared A. Li· 1 shared

Activity by Year

2019-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersBioengineering

B. Liu

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment

J. Li, T. Huang, J. Hua, Q. Wang, Y. Su, P. Chen, S. Bidlingmaier, A. Li, Z. Xie, A. Bidkar, S. Shen, W. Shi, Y. Seo, R. R. Flavell, D. Gioeli, , J. He

This paper develops and tests a CD46-targeted alpha radioimmunotherapy, 212Pb-TCMC-YS5, showing potent tumor growth inhibition and survival improvement in multiple prostate cancer models.

bioRxiv · Oct 14, 2022 · PreprintBioengineering

Treatment of prostate cancer with CD46 targeted 225Ac alpha particle radioimmunotherapy

A. P. Bidkar, S. Wang, K. N. Bobba, E. Chan, S. Bidlingmaier, E. A. Egusa, R. Peter, U. Ali, N. Meher, A. Wadhwa, S. Dhrona, D. Beckford-Vera, Y. Su, R. Tang, L. Zhang, , R. R. Flavell

This study develops and evaluates [225Ac]DOTA-YS5, a radioimmunotherapy for prostate cancer, showing high efficacy in xenograft models but nephrotoxicity at higher doses.

bioRxiv · Oct 13, 2022 · PreprintCancer Biology

A non-ligand surrogate agonist antibody that enhances canonical Wnt signaling and bone regeneration

N.-K. Lee, S. Bidlingmaier, Y. Su, Y. Seo, B. Liu

This paper describes an antibody that enhances Wnt signaling and promotes bone regeneration without requiring exogenous Wnt ligands, showing efficacy in a mouse model of bone loss.

bioRxiv · Sep 25, 2022 · PreprintBioengineering

ALPPL2 is a highly specific and targetable tumor cell surface antigen

Y. Su, X. Zhang, S. Bidlingmaier, C. R. Behrens, N.-K. Lee, B. Liu

The paper identifies ALPPL2 as a highly specific tumor cell surface antigen for mesothelioma and demonstrates its therapeutic potential through an antibody-drug conjugate.

bioRxiv · Jan 7, 2020Cancer Biology

LegoBody: facile generation of bispecific and multi-specific antibodies

S. Lang, Y. Su, S. Bidlingmaier, N.-K. Lee, B. Liu

This study introduces a modular method to generate bispecific and multi-specific antibodies using temporary linkers and proteases, enabling efficient production with desired properties.

bioRxiv · Dec 25, 2019 · PreprintBioengineering